Three-year trial scheme for risk sharing in the drug reimbursement system effective as of 1 January 2019

The Danish Parliament has passed amendments to the Health Act effective as of 1 January 2019 that introduce a three-year trial scheme for risk sharing in the drug reimbursement system.

The amendments to the Health Act aim to strengthen patients' access to reimbursements for prescribed medicinal products, including quicker and easier access to new innovative products. Further, the amendments are expected to benefit the Life Science Sector by enabling general conditional reimbursements for products that do not currently meet the requirements.

During the trial period, the Danish Medicines Agency can grant general conditional reimbursements for medicinal products, on condition of the pharmaceutical company sharing the risk. The National Health Service will cover the expenses for reimbursement for a number of patients who meet the reimbursement conditions and where the treatment value is proportional to the costs. The manufacturer must cover the Regions' expenses for reimbursement for patients exceeding the target population.

Latest news on Life Science

Life Science